Aldevron recently hosted a webinar through FIERCE Biotech titled: Applying Experience - Partnering with Pioneers to Deliver Plasmid for Discovery Through Commercial Application.
Listen below to hear featured presentations from Cindy Biffert, VP of GMP Nucleic Acids Business Unit at Aldevron, Barry Byrne, M.D, P.h.D, Associate Chair of Pediatrics and Professor at UFL, Director of Powell Gene Therapy Center, and Earl and Christy Powell University Chair in Genetics, and Christine Sheaffer, Manufacturing Operations Lead at Spark Therapeutics.
One of the biggest challenges faced by research scientists is ensuring continuity and consistency of processes and plasmids during the early stages of candidate development through commercialization. The webinar dug deep and examined how to best prepare for successful scale-up.
Cindy brought her nearly 20 years of experience immediately to the fore, discussing the vital importance of launching any project with a trusted manufacturing partner – spotlighting Aldevron’s ability to serve clients as they progress through research to commercial. Next, Dr. Byrne dove into AAV vector design considerations, showcasing the importance of high-quality raw materials and how to best gain ITR stability. Christine capped off the presentations by sharing her extraordinary experience in manufacturing LUXTURNA®, a prescription gene therapy product used for the treatment of inherited retinal diseases, providing valuable industry insights and considerations for successful scale-up.
The entire hour-long webinar and Q&A is now accessible for anyone to view and share.